Keywords
Alteplase
Brain
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To carry out a literature review on the risks and benefits of applying alteplase in patients with acute ischemic stroke. Methods: Integrative review, adopting a qualitative and descriptive-exploratory approach. The question was formulated based on the PICO strategy, which helps to identify the essential elements to be considered in the research. Results: Therefore, 10 studies were selected to make up this review. Acute ischemic stroke requires a multidisciplinary and integrated approach. Thrombolytic therapy plays a fundamental role in restoring cerebral blood flow, but its effectiveness is directly related to the time of administration. It is essential that healthcare systems are prepared for rapid diagnosis and treatment. Final considerations: Although alteplase has demonstrated significant benefits in reperfusing compromised brain tissue and improving clinical outcomes, it is essential to consider the risks of bleeding complications, the limited time of administration, the influence of age and stroke severity, as well as the costs involved.
References
ANDERSON CS, et al. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. N Engl J Med., 2016; 374(24): 2313-23.
ARAÚJO DN, et al. Análise do custo-efetividade da trombólise com alteplase no acidente vascular cerebral. Arquivos brasileiros de cardiologia, 2010; 95: 12-20.
BARUZZI AC, et al. Fibrinolíticos: indicações e tratamento das complicações hemorrágicas. Rev. Soc. Cardiol., 2018; 28(4): 421-427.
BERKHEMER OA, et al. A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke. N Engl J Med., 2015; 372(1): 11-20.
CAMPOS DB, et al. Custo-efetividade de alteplase no tratamento de acidente vascular cerebral isquêmico até 4,5 horas após início dos sintomas: perspectiva do Sistema Único de Saúde do Brasil (SUS). J BrasEcon Saúde, 2020; 12(3): 241-54.
CHEN J, et al. Avaliação econômica da alteplase intravenosa para acidente vascular cerebral com tempo de início entre 4,5 e 9 horas. Revista de Cirurgia NeuroIntervencionista, 2023; 1: 46-51.
DINIZ HLN, et al. Acidente vascular cerebral isquêmico: definindo a melhor terapia trombolítica. Revista Eletrônica Acervo Saúde, 2023; 23(2): e11605.
EMBERSON J, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet, 2014; 384(9958): 1929-1935.
HACKE W, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA, 1995; 274(13): 1017-1025.
MANIVA SL e FREITAS CHA. Uso de alteplase no tratamento do acidente vascular encefálico isquêmico agudo: o que sabem os enfermeiros?. Revista Brasileira de Enfermagem, 2012; 65: 474-481.
MILLER SE e WARACH SJ. Evolving Thrombolytics: from Alteplase to Tenecteplase. Neurotherapeutics, 2023; 20(3): 664-678.
NAGATA E. Therapeutic Strategies for Ischemic Stroke. Brain Nerve, 2023; 75(5): 450-455.
PEDRA EFP, et al. Pacientes pós-AVC com e sem trombólise: análise da deglutição na fase aguda da doença. CoDAS, 2020; 32(1): e20180229.
SANDERCOCK P, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet, 2012; 379(9834): 2352-2363.
SAHU A, et al. 327 Tenecteplase versus Alteplase no AVC isquêmico agudo: Encontrando a 'ase' e a 'dosagem' corretas usando a abordagem de meta-análise de rede. Anais de Medicina de Emergência, 2022; 80(4): S139.
SILVA GS e LOPES RD. Manejo da terapia antitrombótica em pacientes com acidente vascular cerebral: onde estamos em 2018? Rev Soc Cardiol., 2018; 28(3): 267-75.
SZYMANSKI P, et al. Trombólise Endovenosa em Acidente Vascular Cerebral isquêmico: uma revisão de literatura. Rev Neurocienc., 2021; 29: 1-16.
WANG CJ, et al. Effectiveness of a Quality Improvement Intervention on Reperfusion Treatment for Patients With Acute Ischemic Stroke: A Stepped-Wedge Cluster Randomized Clinical Trial. JAMA, 2023; 6(6): e2316465.
WARDLAW JM, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet, 2012; 379(9834): 2364-72.
WU H, et al. Effect of the interaction between atrial fibrillation and rt-PA dose on the prognosis of acute ischaemic stroke with intravenous thrombolysis. Postgrad Med J., 2023; 99(1172): 588-594.